MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Tevogen Bio Holdings Inc. (NASDAQ: TVGN)*
Organization & Developments: Tevogen Bio
Parents
Tevogen Bio Holdings Inc. (NASDAQ: TVGN)*
Children
*Advancing its ExacTcell technology platform, which focuses on precision T cell therapies to support uninterrupted oncology treatments
*Clinical-stage immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
2024: Tevogen Bio Claims $10 Billion IP Potential But Hinges On Monetization
2024: Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical Lesions
2024: Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections
Jumps
Finance & Acquisition: Tevogen Bio
Key People: Tevogen Bio